KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Net Margin (2016 - 2026)

Bristol Myers Squibb has reported Net Margin over the past 18 years, most recently at 23.32% for Q1 2026.

  • Quarterly Net Margin rose 134.0% to 23.32% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 15.0% through Mar 2026, up 382.0% year-over-year, with the annual reading at 14.64% for FY2025, 3314.0% up from the prior year.
  • Net Margin was 23.32% for Q1 2026 at Bristol Myers Squibb, up from 8.69% in the prior quarter.
  • Over five years, Net Margin peaked at 23.32% in Q1 2026 and troughed at 100.36% in Q1 2024.
  • The 5-year median for Net Margin is 14.33% (2022), against an average of 7.77%.
  • Year-over-year, Net Margin plummeted -12036bps in 2024 and then surged 12234bps in 2025.
  • A 5-year view of Net Margin shows it stood at 17.75% in 2022, then decreased by -16bps to 14.87% in 2023, then plummeted by -96bps to 0.62% in 2024, then soared by 1311bps to 8.69% in 2025, then soared by 168bps to 23.32% in 2026.
  • Per Business Quant, the three most recent readings for BMY's Net Margin are 23.32% (Q1 2026), 8.69% (Q4 2025), and 17.96% (Q3 2025).